Cargando…

Progress in the Development of Anti-tissue Factor Pathway Inhibitors for Haemophilia Management

The unprecedented progress in addressing unmet needs in haemophilia care to date includes developing several novel therapies that rebalance haemostasis by restoring thrombin generation in patients with haemophilia A or B with and without inhibitors. These novel therapies are FVIII mimetics, antithro...

Descripción completa

Detalles Bibliográficos
Autor principal:	Mahlangu, Johnny N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8131856/ https://www.ncbi.nlm.nih.gov/pubmed/34026796 http://dx.doi.org/10.3389/fmed.2021.670526

Ejemplares similares

Long‐term safety and efficacy of the anti‐tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results
por: Mahlangu, Johnny, et al.
Publicado: (2022)

Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B
por: Mahlangu, Johnny N.
Publicado: (2018)

A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia
por: Mahlangu, Johnny N., et al.
Publicado: (2022)

Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B
por: Mahlangu, Johnny, et al.
Publicado: (2021)

Health‐related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors—Results from the HAVEN 2 study
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab
por: Chowdary, Pratima
Publicado: (2018)

Comparison of joint status using ultrasound assessments and Haemophilia Joint Health Score 2.1 in children with haemophilia
por: Li, Yanju, et al.
Publicado: (2023)

Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies
por: Parnes, Aric, et al.
Publicado: (2021)

European principles of inhibitor management in patients with haemophilia
por: Giangrande, P. L. F., et al.
Publicado: (2018)

Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors
por: Kempton, Christine, et al.
Publicado: (2021)

RNA sequencing suggests that non‐coding RNAs play a role in the development of acquired haemophilia
por: Tigu, Adrian Bogdan, et al.
Publicado: (2023)

The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors
por: Escobar, Miguel, et al.
Publicado: (2021)

The potential correlation between patient-reported symptoms and the use of additional haemostatic medication for joint bleeding in haemophilia patients with inhibitors: a post hoc exploratory analysis of recombinant activated factor VII data from the ADEPT2 trial
por: Lentz, Steven R., et al.
Publicado: (2017)

Switching treatments in haemophilia: is there a risk of inhibitor development?
por: Santagostino, Elena, et al.
Publicado: (2015)

The profile of patients with haemophilia managed at a haemophilia treatment centre in Pretoria, Gauteng
por: Mafisa, Lethukuthula, et al.
Publicado: (2022)

The evolution of factor VIIa in the treatment of bleeding in haemophilia with inhibitors
por: Meeks, Shannon L., et al.
Publicado: (2019)

Report of Two Cases of Acquired Idiopathic Haemophilia
por: Silva, Clara, et al.
Publicado: (2021)

Management of haemophilia A with inhibitors: A regional cross‐talk
por: Peyvandi, Flora, et al.
Publicado: (2022)

Sexual activity and the adolescent with haemophilia
por: Banchev, Atanas
Publicado: (2023)

Osteoporosis management and falls prevention in patients with haemophilia: Review of haemophilia guidelines
por: Petkovic, Madison J., et al.
Publicado: (2022)

BAY 81‐8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years
por: Mahlangu, Johnny, et al.
Publicado: (2020)

Health‐related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non‐interventional study (NIS)
por: Mahlangu, Johnny, et al.
Publicado: (2019)

Haemophilia - diagnosis and management challenges
por: Shetty, Shrimati
Publicado: (2014)

Pain and pain management in haemophilia
por: Auerswald, Günter, et al.
Publicado: (2016)

Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study
por: Nolan, Beatrice, et al.
Publicado: (2020)

The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies
por: Skinner, Mark W., et al.
Publicado: (2021)

Hæmophilia
Publicado: (1905)

Hæmophilia
por: Ruggles, S. D.
Publicado: (1902)

Hæmophilia
por: Porter, Charles A.
Publicado: (1900)

Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX
por: Rocino, Angiola, et al.
Publicado: (2017)

LPS-induced expression and release of monocyte tissue factor in patients with haemophilia
por: Holstein, Katharina, et al.
Publicado: (2020)

European principles of inhibitor management in patients with haemophilia: implications of new treatment options
por: Hermans, C., et al.
Publicado: (2020)

Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult‐to‐treat patients
por: Ljung, Rolf, et al.
Publicado: (2018)

Haemophilia A: A Review of Clinical Manifestations, Treatment, Mutations, and the Development of Inhibitors
por: Sarmiento Doncel, Samuel, et al.
Publicado: (2023)

Haemophilia in the developing countries: the Iranian experience
por: Eshghi, Peyman, et al.
Publicado: (2010)

Haemophilia in France: Modelisation of the Clinical Pathway for Patients
por: Beny, Karen, et al.
Publicado: (2022)

Factor VIII companion diagnostic for haemophilia
por: Hu, Chunxiao, et al.
Publicado: (2022)

Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors
por: Pipe, Steven W., et al.
Publicado: (2022)

Legg on Hæmophilia
Publicado: (1873)

Malarious Hæmophilia
Publicado: (1890)

Cannot write session to /tmp/vufind_sessions/sess_f1bbcod0u8bphemh7f53i427mj